Form 4: NovaBay CEO Kazley Boosts Stake via Conversions & Warrants

NovaBay Pharmaceuticals CEO Michael Kazley significantly increased his indirect beneficial ownership through the conversion of preferred stock and the purchase of pre-funded warrants.

Summary

• Michael Kazley, CEO, Director, and 10% Owner of NovaBay Pharmaceuticals, Inc. (NBY), reported significant changes in his indirect beneficial ownership.
• On October 21, 2025, 220,663 shares of Series D Non-Voting Convertible Preferred Stock were converted into 35,306,080 shares of Common Stock.
• Concurrently, 134,375 shares of Series E Non-Voting Convertible Preferred Stock were converted into 21,500,000 shares of Common Stock.
• These conversions resulted in an acquisition of 56,806,080 shares of Common Stock indirectly owned by R01 Entities.
• On October 16, 2025, R01 LP purchased 2,702,703 pre-funded warrants to acquire Common Stock.
• The purchase price for these warrants was $1.10 per warrant, which represents 110% of the closing price of the Common Stock on the day prior to issuance, less the $0.01 exercise price.
• The pre-funded warrants are exercisable after January 1, 2026, subject to stockholder approval.
• All reported securities are indirectly beneficially owned by R01 Entities, where Michael Kazley is the managing member of R01 Capital Manager.

Sentiment

Score: 7

Explanation: The significant increase in beneficial ownership by the CEO, through both conversions and warrant purchases at a premium, indicates strong insider confidence. However, the future exercise of warrants is subject to stockholder approval, introducing a minor contingency.

Positives

• Significant increase in indirect beneficial ownership by CEO Michael Kazley, indicating strong insider confidence.
• Conversion of preferred stock into common stock simplifies the capital structure.
• The purchase of pre-funded warrants at a premium to the prior day's closing price (110%) suggests a positive outlook on future stock performance by the insider.

Negatives

• Conversion of preferred stock into common stock could lead to dilution for existing common stockholders.
• The exercise of pre-funded warrants is subject to future stockholder approval, introducing a contingency.

Risks

• The exercise of the pre-funded warrants is subject to stockholder approval, meaning the full benefit of the warrant purchase is not yet guaranteed.

Future Outlook

Pre-funded warrants acquired by R01 LP are exercisable for shares of Common Stock at any time after January 1, 2026, contingent upon receiving stockholder approval.

Industry Context

This filing primarily details insider transactions and capital structure adjustments for NovaBay Pharmaceuticals, Inc. It does not provide information directly related to broader industry trends or competitive landscape analysis.

Corporate Governance

Related Party Transactions

• Michael Kazley, as CEO, Director, and 10% Owner, is the managing member of R01 Capital Manager, which is part of the R01 Entities.
• The conversion of preferred stock and the purchase of pre-funded warrants were conducted by R01 Entities, making these related-party transactions.

Stakeholder Impact

• Shareholders: The conversion of preferred stock into common stock increases the number of outstanding common shares, potentially leading to dilution.
• Shareholders: Increased indirect beneficial ownership by the CEO may signal stronger alignment of management interests with common shareholders.
• Company: The purchase of pre-funded warrants represents a capital inflow to the company.

Next Steps

• Stockholder approval will be required for the exercise of the pre-funded warrants.

Key Dates

Recommendation

The significant increase in indirect beneficial ownership by CEO Michael Kazley, through both preferred stock conversions and the purchase of pre-funded warrants at a premium, signals strong insider confidence in NovaBay Pharmaceuticals. While this is a positive indicator, a 'hold' recommendation is appropriate as this Form 4 primarily details insider transactions and capital structure adjustments, rather than comprehensive financial performance or strategic updates that would warrant a 'buy' or 'sell' rating without further analysis of the company's broader financial health and market position.

Keywords

NovaBay Pharmaceuticals, NBY, Michael Kazley, Form 4, Insider Trading, Stock Conversion, Pre-Funded Warrants, Beneficial Ownership, R01 Entities, Preferred Stock, Common Stock, Corporate Governance